



## Early View

Original article

### **Experimental dyspnea interferes with locomotion and cognition: a randomised trial**

David Lawi, Elise-Lozeron Dupuis, Gregory Berra, Gilles Allali, Thomas Similowski, Dan Adler

Please cite this article as: Lawi D, Dupuis E-L, Berra G, *et al.* Experimental dyspnea interferes with locomotion and cognition: a randomised trial. *Eur Respir J* 2020; in press (<https://doi.org/10.1183/13993003.00054-2020>).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020

## Experimental dyspnea interferes with locomotion and cognition: a randomised trial

Lawi David<sup>1</sup>, Dupuis-Lozeron Elise<sup>2,7</sup>, Berra Gregory<sup>1</sup>, Allali Gilles<sup>3,4,7</sup>, Similowski Thomas<sup>5,6</sup>, Adler Dan<sup>1,7</sup>

<sup>1</sup> Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland.

<sup>2</sup> Clinical Research Centre & Division of Clinical Epidemiology, Department of Health and Community Medicine, Geneva University Hospitals, Geneva, Switzerland.

<sup>3</sup> Department of Neurology, Geneva University Hospitals, Geneva, Switzerland.

<sup>4</sup> Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Bronx, NY, USA.

<sup>5</sup> AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Intensive Care Unit and Respiratory Division (Département "R3S"), Paris, France.

<sup>6</sup> Sorbonne University, UPMC Paris 06, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.

<sup>7</sup> University of Geneva Faculty of Medicine, Geneva, Switzerland.

**Submitted to:** *European Respiratory Journal*

### **Correspondence:**

Dan Adler, MD

Division of Pulmonary Diseases

Geneva University Hospitals

4 Rue Gabrielle-Perret-Gentil

1211 Geneva 14 / Switzerland

**Keywords:** dyspnea, locomotion, cognition

## Abstract

**Background:** Chronic respiratory diseases are associated with cognitive dysfunction, but whether dyspnea by itself negatively impacts on cognition has not been demonstrated. Cortical networks engaged in subjects experiencing dyspnea are also activated during other tasks that require cognitive input and may provoke a negative impact through interference with each other.

**Methods:** This crossover randomised trial investigated whether experimentally-induced dyspnea would negatively impact on locomotion and cognitive function among 40 healthy adults. Crossover conditions were unloaded breathing or loaded breathing using an inspiratory threshold load. To evaluate locomotion, participants were assessed by the Timed Up and Go test. Cognitive function was assessed by categorical and phonemic verbal fluency tests, the Trail Making Test A and B (executive function), the CODE test from the WAIS-IV (processing speed), and by direct and indirect digit span (working memory).

**Results:** The mean time difference to perform the Timed Up and Go test between unloaded and loaded breathing was -0.752 sec (-1.012 to -0.492;  $p < 0.001$ ). Executive function, processing speed and working memory performed better during unloaded breathing, particularly for subjects starting first with the loaded breathing condition.

**Conclusion:** Our data suggest that respiratory threshold loading to elicit dyspnea had a major impact on locomotion and cognitive function in healthy adults.

### **Tweetable abstract@ERSpublication:**

Acute experimental dyspnea can negatively impact on locomotion/cognition through shared neural substrates. There is a need for clinical interventions to improve non-respiratory symptoms of chronic respiratory diseases by focusing on alleviating dyspnea.

## Introduction

### Background

Chronic respiratory diseases, in particular chronic obstructive pulmonary disease (COPD), are associated with cognitive dysfunction [1, 2]. In parallel, gradual ageing of the general population strongly impacts on the prevalence of neurodegenerative and cerebrovascular conditions affecting cognition [3]. As the prevalence of COPD increases with age [4], it is important to understand whether older patients with symptomatic respiratory diseases present cognitive dysfunction due to ageing or if there is a true causal association between symptomatic respiratory diseases and cognitive function. Several hypotheses have been advanced to explain the underlying pathophysiology of cognitive dysfunction in COPD including modified arterial blood gases [5], persistent cigarette smoking, comorbid vascular diseases [6], loss of hippocampal volume and inflammatory mediator-related neuronal damage [7, 8]. An association between reduced lung function, impaired cognition and a greater risk of incident dementia has been also reported [9-11].

Dyspnea, the most common symptom of respiratory diseases, has been associated with disrupted brain activity [12], self-consciousness [13, 14] and gait control [15]. However, the effect of dyspnea itself, an “all-consuming and life changing” experience, on cognition is less well studied. A first set of studies have demonstrated that experimental dyspnea impairs affective picture processing [16], response inhibition [17] and memory and face recognition [18, 19], but more research is needed to study important aspects of dyspnea-cognition interactions, including the interaction with locomotion.

In healthy humans, normal breathing stems from automatic brainstem neural processes and does not give rise to conscious perception or require any motor or sensory cortical resources [13, 14, 20]. Under certain circumstances, such as voluntary respiratory movements or during speech, breathing can be operated by cortico-subcortical networks [21]. Cortically-driven breathing has also been described in reaction to changes in the mechanical properties of the respiratory system [20, 22]. Externally-applied inspiratory and expiratory constraints also give rise to respiratory-related motor cortical activities [20, 23]. The corresponding network involves the primary motor cortex, the supplementary motor area and corticospinal projections. In addition, recent evidence suggests that cortical activation, as demonstrated by an electroencephalogram, may make a significant contribution to quiet breathing in older age [24].

Similar to breathing, gait is considered to be an automatic function in young adults that should not depend on cognition [25]. However, in elderly patients and those suffering from neuropsychiatric conditions, gait control relies on cognitive function, particularly executive functions [26, 27], and shares similar cortical networks activated by a respiratory load [28, 29]. Thus, the cortical networks engaged in response to inspiratory loading are also activated during complex locomotor tasks that require cognitive input, such as gait. As a reliable measure of locomotion, the Timed Up and Go test (TUG) has been largely used in the elderly population [30] to identify poor clinical outcomes, such as cognitive impairment or dementia [31, 32]. More recently, an imaginary version of the TUG (iTUG) has been developed to evaluate the central control of locomotion [33].

In a preliminary study [15], we showed that progressive inspiratory threshold loading increased linearly the time to perform the TUG and suggested that a competition for cortical resources, among other mechanisms, may account for the observed breathing-locomotion interference. This study is designed to test the hypothesis that laboratory-induced dyspnea in healthy young subjects would impact on gait control and cognitive function.

## Methods

### *Study design*

This randomised, two-condition, two-period crossover study was conducted at Geneva University Hospitals (Geneva, Switzerland). The study was approved by the local ethics committee on research involving humans and registered on the Swiss national clinical trials portal (ID 2016-00807). All participants provided written informed consent in accordance with Swiss Federal Laws on Human Research and Clinical Trials Ordinance.

### *Subjects*

Forty highly-educated subjects were recruited from the Geneva University campus. Individuals aged from 18-40 years old and of French mother tongue were eligible for study inclusion. Exclusion criteria were a physician's diagnosis of a respiratory, neurological or psychiatric disorder and pregnancy. Subjects were also excluded if considered unable to perform the TUG. During enrollment, all eligible participants underwent a medical examination by a physician and data were collected on past medical history, age, gender, body mass index (kg/m<sup>2</sup>), FEV<sub>1</sub>, forced vital capacity, SpO<sub>2</sub>, sniff nasal inspiratory pressure (SNIP) and mouth inspiratory pressure (MIP) [34].

### *Experimental dyspnea*

From February 2017 to May 2019, participant enrollment, randomisation and testing took place at the respiratory physiology laboratory of Geneva University Hospitals. Lung function parameters were assessed using a portable spirometer (SpiroTel® with WinSpiro PRO® software version 7.3, Rome, Italy). SNIP and maximal MIP were measured using a microRPM® device (CareFusion, Hoechst, Germany) [34]. Dyspnea was induced by an inspiratory threshold load (POWERbreathe Classic®, PowerBreathe Ltd, London, UK) connected to a commercial comfortable orofacial mask (Resmed AcuCare™ F1-0, Sydney, Australia) designed for non-invasive ventilation. The inspiratory threshold load device provides an inspiratory pressure ranging from 10 to 170 cmH<sub>2</sub>O (9 predefined levels) that needs to be overcome by the study participant at every breath during the experimentally-induced dyspnea sequence of the trial. The inspiratory threshold device has an inbuilt one-way expiratory valve to prevent CO<sub>2</sub> rebreathing. Before the experiment started, the inspiratory load was progressively increased to a predefined dyspnea rating of 6/10 on a visual analog scale. Before and after each period of experimentally-induced dyspnea, subjects completed the Multidimensional Dyspnea Profile (MDP) questionnaire [35], which assesses dyspnea during a specific time or condition and is a proven valid instrument for clinical and laboratory research [36].

### *Locomotion*

We used the TUG as described by Podsiadlo et al [30] and its imagined version validated by Beauchet et al [33] to assess locomotion. On command, the subject had to stand up from an armchair, walk 3 metres, then turn and sit down again on the chair. For the iTUG, on command, subjects had to imagine the TUG and signal to the investigator its mental completion. The difference in time (i.e. delta time) between TUG and iTUG conditions was calculated according to the following formula  $[(TUG - iTUG) / (TUG + iTUG / 2)]$  and was also used as an outcome variable. Cognitive status is strongly associated with TUG, iTUG and delta time [31, 33, 37, 38] as these tasks place additional cognitive challenges on brain function.

### *Cognition*

Categorical and phonemic verbal fluencies tests [39], as well as the Trail Making Test (TMT) A and B [40], were used to assess executive functions. During categorical verbal fluency tests, subjects had 2 minutes to produce the maximum number of words from the “animal” category. For the phonemic verbal fluency test, the subjects had to produce the maximum number of words starting with the letter “P” during 2 minutes. For the TMT A, subjects had to connect numbered bullets as fast as possible in an increasing

manner. The same principle was applied for TMT B, except that the subject had to alternatively connect a number to a letter in an increasing way.

Processing speed was assessed by the CODE test from the Wechsler Adult Intelligence Scale (WAIS-IV) [41, 42] for which subjects had to copy in 2 minutes the maximum number of symbols associated with numbers on an answer sheet with numbers without the symbols.

Working memory was assessed by direct and indirect digit span [41, 42]. During the direct digit span, subjects had to repeat in the same order a series of numbers read by the examiner and in the indirect digit span, subjects had to repeat the series of number read by the investigator in reverse order.

### *Intervention*

The randomisation sequence was computer-generated using the permuted block method with blocks of varying size (4 to 6). Using a sealed, opaque, envelope randomisation system, we assigned subjects in a 1:1 ratio to receive either the sequence “loaded breathing/unloaded breathing” or the sequence “unloaded breathing/loaded breathing” (figure 1). During the first period (either experimentally-loaded breathing or unloaded breathing), subjects had to complete the locomotion and cognitive tests in a fixed order. During the loaded breathing period, subjects wore the orofacial mask connected with the respiratory load at a predefined level of resistance. During the unloaded breathing period, subjects wore the same mask without the respiratory load. During the second period, subjects were switched to the complementary condition (either unloaded or loaded breathing) and the exact same tests in the same order were completed. Oxygen saturation was continuously monitored during both periods with pulse oximetry (Konica Minolta Pulsox-300i, Konica Minolta Sensing, Osaka, Japan).

### *Predetermination of study endpoints*

The primary endpoint was the time to perform TUG and iTUG (measured in seconds). Secondary endpoints were the fluency tests (measured by the number of correct words), TMT A and B (measured in seconds), CODE test (measured by the number of correct associations) and digit span (measured by the number of correct sequence of numbers).

### *Statistical analysis*

The study was designed to show a difference of 0.5 sec to perform TUG between the two experimental conditions with a standard deviation of the difference of 1 sec according to our previous findings [15]. To show this difference in a crossover design using a paired t-test with a two-sided significance level of 0.05 and a power of 0.8, enrollment of 36 subjects was required. The effect of dyspnea on each test was

assessed using a linear mixed-effects model with a random intercept for each participant. In addition to the experimental condition (loaded breathing vs unloaded breathing), each model also included the experimental sequence (starting the experiment with unloaded or loaded breathing) and the interaction between the experimental sequence and the experimental condition as fixed effects. The statistical significance of the interactions was assessed using the likelihood ratio test. All p-values were two-sided and statistical significance was set at a p-value of 0.05. All analyses were performed using R for Windows (version 3.6.1) [43] with the lme4 [44], emmeans Lenth [45] and tidyverse [46] packages.

## Results

Forty healthy subjects were randomly assigned either to the sequence “loaded breathing/unloaded breathing” (n=20) or to “unloaded breathing/loaded breathing” (n=20). Baseline characteristics were similar between groups (table 1). Experimentally-induced dyspnea (self-rated intensity of 6/10 on a visual analog scale) was obtained in all subjects at a median threshold level of 4.75 (interquartile range [IQR] 3.00-7.62) on the inspiratory threshold device. Oxygen saturation was stable during the entire experiment with no drop during experimentally-induced dyspnea (SpO<sub>2</sub> 99%; IQR 98-100]). Differences of locomotion and neuropsychological tests performance between conditions are reported in Table 2. Mean estimated value  $\pm$  SD for each test according to respiratory conditions are provided in Table S1 of the supplementary material.

### *Motor function*

Mean time to perform TUG was  $8.97 \pm 1.35$  (sec) during unloaded breathing and  $9.72 \pm 1.54$  (sec) during loaded breathing, with an estimated difference of -0.75 (sec) (95% CI -1.01 to -0.49;  $p < 0.001$ ) between conditions (figure 2, panel A). An interaction between experimental conditions (unloaded or loaded breathing) and experimental sequences (starting the experiment with unloaded breathing or starting with loaded breathing) was demonstrated for the TUG ( $p = 0.005$ ) (figure 2, panel B). We did not observe a difference between conditions or an interaction for iTUG. Conversely, delta time increased with loaded breathing compared with unloaded breathing (estimated difference = -0.08 (sec); 95% CI -0.14 to -0.02;  $p = 0.011$ ), with no interaction between conditions and sequences.

### *Neuropsychological tests*

*Executive function:* Categorical and verbal fluencies tests both demonstrated the same profile. While subjects were able to produce more words during unloaded compared to loaded breathing, the effect of the experimental condition was more pronounced for those who started the experiment with loaded



breathing as a result of an interaction between the experimental condition and the experimental sequence ( $p=0.003$  for verbal fluency and  $p=0.004$  for categorical fluency). For TMT A, although no differences in time to perform the test between experimental conditions were observed, subjects who started the experiment with loaded breathing much improved their time to perform it with unloaded breathing as a result of an interaction between the experimental condition and the experimental sequence ( $p<0.001$ ). For TMT B, no differences in time to perform the test between experimental conditions were observed. As for TMT A, an interaction was found between the experimental condition and the experimental sequence ( $P<0.001$ ) for TMT B. However subjects who started the experiment with the unloaded breathing performed better during the second condition compared to those who started with loaded breathing.

*Processing speed:* Overall, the number of correct associations performed during the CODE test seemed to be higher during unloaded compared to loaded breathing (difference of correct associations between conditions: 4.13; 95% CI -0.27 to 8.52;  $p=0.07$ ). Furthermore, subjects who started the experiment with loaded breathing much improved their performance with unloading as a result of an interaction between the experimental condition and the experimental sequence ( $p<0.001$ ).

*Working memory:* No differences between conditions were observed for both direct and indirect digit span. However, subjects who started the experiment with loaded breathing much improved their performance with unloading as a result of an interaction between the experimental condition and the experimental sequence ( $p=0.03$  for direct digit span and  $p=0.008$  for indirect digit span for both).

## Discussion

In this randomised crossover trial of experimental dyspnea in healthy subjects, we found that experimental dyspnea to a predetermined intensity of 6/10 on a visual analog scale had a major impact on locomotion and cognitive function in a sample of highly educated younger adults. Our data support previous evidence of dyspnea-cognition interactions [15-18] and suggest a plausible causal association between dyspnea and brain function leading to altered locomotion and cognition. The crossover design also highlighted that alleviation of dyspnea has a positive effect on locomotion and cognition.

Among locomotion parameters, gait speed is considered as the “sixth vital sign” [47] and mainly depends on exercise capacity related to cardiorespiratory fitness, but also on the integrity of musculoskeletal, peripheral and central nervous systems. Reduced gait speed is associated with a poor clinical outcome in ageing and associated with mortality [48]. Only a few studies have focused on gait speed in respiratory

diseases as the 6-min walking test and the incremental shuttle walk are historically so important to quantify cardiorespiratory reserve and exercise tolerance in this field. However, gait speed, as measured by the 4-metre gait speed, correlates with exercise capacity, dyspnea and health-related quality of life [49] and is a predictor of hospital readmission for acute exacerbation of COPD [50]. The 4-metre gait speed is also responsive to pulmonary rehabilitation [51] and has been proposed as a promising functional assessment in COPD to inform the clinician about many functional aspects and overall outcome [52].

As suggested in a previous study of our group, but with no formal demonstration [15], dyspnea might independently impact on gait through shared neural networks with cognitive functions. In the present study, experimentally-induced dyspnea increased time to perform TUG and consistently impacted on cognition across all neuropsychological tests particularly for subjects starting the experiment with the loaded breathing condition. Indeed, dual-tasking experimental paradigms state that two tasks performed simultaneously may have a negative impact on each other when they both depend on similar cortical networks [53] as demonstrated here. The impact of dyspnea on the time to perform the TUG (+8.4% from baseline) and the neuropsychological tests in our trial is large, especially when considering that only highly educated young subjects were included. Recent evidence from a large cohort also suggests that challenging gait speed with a concurrent cognitive task may represent a sensitive marker in younger subjects to assess brain health and cognitive function. This calls for rethinking locomotion and gait speed not only as a geriatric index of frailty, but also as a surrogate marker of brain functioning in younger subjects or in patients with chronic respiratory diseases. For instance, developing a test to challenge gait speed with a respiratory load at hospital discharge in patients surviving an exacerbation of COPD could inform the clinician about which patient is more likely to present or to develop poor cognition that would place him/her at risk of poor adherence to medical treatment and thus at increased risk of readmission [54].

The current observations that dyspnea is associated with poor executive function, attention and processing speed are in line with previous findings showing that chronic respiratory diseases are associated with cognitive impairment. However, it has consistently been reported that other intermediate factors such as altered blood gases [5, 55], reduced lung function [11, 56], persistent cigarette smoking [57], vascular disease [10, 58, 59], loss of hippocampal volume and inflammatory mediator-related neuronal damage [60, 61] are responsible for this association with cognition. As lung dysfunction and disease severity do not fully explain the development of cognitive impairment, our

findings expand current knowledge by highlighting that dyspnea *per se* is independently associated with locomotion and cognition in a plausible causal relationship.

Alleviation of dyspnea consistently improved locomotion and cognition across all neuropsychological tests in our study, suggesting a possible learning effect. However, this observation also suggests that addressing chronic or persistent breathlessness as a syndrome with a specific treatment in addition to treating the underlying respiratory condition may also improve outcomes [62, 63].

The dyspnea-inactivity vicious circle model in COPD is now supported by real-life data that has bridged a gap of knowledge by identifying dyspnea as a major endpoint in a chain of events leading to disability [64, 65]. More research is needed to determine where cognitive dysfunction stands in this chain of events and if a specific intervention on dyspnea itself might reverse the vicious circle. At present, opiates are the only evidence-based pharmacologic treatment to target dyspnea. Immediate-release morphine has been shown to improve exercise-induced breathlessness and exercise endurance in a significant proportion of COPD patients with advanced disease [66]. Our findings may support that such a treatment would also have an impact on locomotion and cognition, while respiratory mechanics are unchanged, thus providing a definitive demonstration that dyspnea impacts on cognitive function, but further studies are needed (MORDYC trial: NCT02429050).

Our study has some potential limitations. First, we did not assess any modification of brain activity by electroencephalography or functional MRI, nor did we assess PaCO<sub>2</sub> (or a surrogate) during the experiment. Indeed, we considered that using a randomised trial of experimentally-induced dyspnea would provide sufficient evidence to infer that dyspnea impacts on cognition and locomotion. It is now firmly established that respiratory loading modifies respiratory-related cortical activity [67-71] and recent evidence suggests that such a modification is associated with impaired cognitive performance (VENTIPSY trial: NCT03095729; Prof. Thomas Similowski personal communication). Moreover, the respiratory system has a remarkable ability to fight externally applied mechanical loads to maintain alveolar ventilation within normal range [72]. Second, our findings cannot be generalized to an older population with chronic respiratory diseases, in which dyspnea at an intensity of 4/10 is already clinically relevant [73]. Indeed, we specifically focused on highly functioning young adults. Interestingly, it was easy to artificially induce cognitive impairment in young healthy brains with a simple method of respiratory loading and this should certainly open up research avenues devoted to exploring the interaction between dyspnea and cognition in older adults. Third, acute dyspnea was induced in a secured experimental setting and does not reflect the chronic condition associated with respiratory

diseases. Therefore, our results may not reflect the interactions among physiological, psychological, social and environmental factors involved in secondary physiological and behavioural responses to refractory dyspnea in the clinical setting.

## Conclusions

Acute experimental dyspnea can negatively impact on locomotion and cognition in a reversible manner by challenging shared neural substrates. These findings challenge current understanding of non-respiratory symptoms of chronic respiratory diseases and will provide a rationale for future clinical interventions aiming to improve locomotion and cognition by focusing on alleviating dyspnea.

## Acknowledgements

The study is funded by The Geneva Pulmonary League (grant no. 73732). The authors would like to thank Rosemary Sudan for editorial assistance.

## Author contributions:

### **David LAWI:**

- Study conception and design, acquisition of data, analysis and interpretation of data, drafting of manuscript.

### **Elise DUPUIS-LOZERON**

- Study conception and design, analysis and interpretation of data, critical manuscript revision.

### **Gregory BERRA**

- Study conception and design, acquisition of data, critical manuscript revision.

### **Gilles ALLALI**

- Study conception and design, interpretation of data, critical manuscript revision.

### **Thomas SIMILOWSKI**

- Study conception and design, interpretation of data, critical manuscript revision.

### **Dan ADLER**

- Study conception and design, analysis and interpretation of data, drafting and critical revision of manuscript.

## References

1. Dodd, J.W., *Lung disease as a determinant of cognitive decline and dementia*. Alzheimer's research & therapy, 2015. **7**(1): p. 32-32.
2. Villeneuve, S., et al., *Mild cognitive impairment in moderate to severe COPD: a preliminary study*. Chest, 2012. **142**(6): p. 1516-1523.
3. Langa, K.M. and D.A. Levine, *The diagnosis and management of mild cognitive impairment: a clinical review*. Jama, 2014. **312**(23): p. 2551-61.
4. Lopez-Campos, J.L., W. Tan, and J.B. Soriano, *Global burden of COPD*. Respiriology, 2016. **21**(1): p. 14-23.
5. Thakur, N., et al., *COPD and cognitive impairment: the role of hypoxemia and oxygen therapy*. Int J Chron Obstruct Pulmon Dis, 2010. **5**: p. 263-9.
6. Maclay, J.D. and W. MacNee, *Cardiovascular disease in COPD: mechanisms*. Chest, 2013. **143**(3): p. 798-807.
7. Andrianopoulos, V., et al., *Cognitive impairment in COPD: should cognitive evaluation be part of respiratory assessment?* Breathe (Sheffield, England), 2017. **13**(1): p. e1-e9.
8. Lawi, D., et al., *[COPD and cognitive impairment]*. Rev Med Suisse, 2018. **14**(627): p. 2066-2069.
9. Chyou, P.-H., et al., *Pulmonary function measures as predictors and correlates of cognitive functioning in later life*. American Journal of Epidemiology, 1996. **143**(8): p. 750-756.
10. Pathan, S.S., et al., *Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study*. European journal of neurology, 2011. **18**(6): p. 888-898.
11. Lutsey, P.L., et al., *Impaired Lung Function, Lung Disease, and Risk of Incident Dementia*. American journal of respiratory and critical care medicine, 2019. **199**(11): p. 1385-1396.
12. Raux, M., et al., *Functional magnetic resonance imaging suggests automatization of the cortical response to inspiratory threshold loading in humans*. Respiratory Physiology & Neurobiology, 2013. **189**(3): p. 571-580.
13. Allard, E., et al., *Interferences between breathing, experimental dyspnoea and bodily self-consciousness*. Scientific Reports, 2017. **7**(1): p. 9990.
14. Adler, D., et al., *Breathing and sense of self: visuo-respiratory conflicts alter body self-consciousness*. Respir Physiol Neurobiol, 2014. **203**: p. 68-74.
15. Nierat, M.C., et al., *When Breathing Interferes with Cognition: Experimental Inspiratory Loading Alters Timed Up-and-Go Test in Normal Humans*. PLoS One, 2016. **11**(3): p. e0151625.
16. Juravle, G., et al., *Neural responses to affective pictures while anticipating and perceiving respiratory threat*. Psychophysiology, 2017. **54**(2): p. 182-192.
17. Sucec, J., et al., *The Effects of Repeated Dyspnea Exposure on Response Inhibition*. Frontiers in physiology, 2019. **10**: p. 663-663.
18. Vinckier, F., C. Morélot-Panzini, and T. Similowski, *Dyspnoea modifies the recognition of fearful expressions by healthy humans*. The European respiratory journal, 2018. **51**(2): p. 1702253.
19. Sucec, J., et al., *The effect of dyspnea on recognition memory*. International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2020. **148**: p. 50-58.
20. Raux, M., et al., *Electroencephalographic evidence for pre-motor cortex activation during inspiratory loading in humans*. J Physiol, 2007. **578**(Pt 2): p. 569-78.
21. Tremoureux, L., et al., *Electroencephalographic evidence for a respiratory-related cortical activity specific of the preparation of prephonatory breaths*. Respir Physiol Neurobiol, 2014. **204**: p. 64-70.

22. Raux, M., et al., *Cerebral cortex activation during experimentally induced ventilator fighting in normal humans receiving noninvasive mechanical ventilation*. *Anesthesiology*, 2007. **107**(5): p. 746-55.
23. Morawiec, E., et al., *Expiratory load compensation is associated with electroencephalographic premotor potentials in humans*. *J Appl Physiol (1985)*, 2015. **118**(8): p. 1023-30.
24. Nguyen, D.A.T., et al., *Inspiratory pre-motor potentials during quiet breathing in ageing and chronic obstructive pulmonary disease*. *J Physiol*, 2018. **596**(24): p. 6173-6189.
25. Hausdorff, J.M., *Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking*. *Hum Mov Sci*, 2007. **26**(4): p. 555-89.
26. Allali, G., et al., *Changes in gait while backward counting in demented older adults with frontal lobe dysfunction*. *Gait Posture*, 2007. **26**(4): p. 572-6.
27. Beauchet, O., et al., *Gait control: a specific subdomain of executive function?* *Journal of NeuroEngineering and Rehabilitation*, 2012. **9**(1): p. 12.
28. Snijders, A.H., et al., *Neurological gait disorders in elderly people: clinical approach and classification*. *Lancet Neurol*, 2007. **6**(1): p. 63-74.
29. Allali, G., et al., *The neural basis of age-related changes in motor imagery of gait: an fMRI study*. *J Gerontol A Biol Sci Med Sci*, 2014. **69**(11): p. 1389-98.
30. Podsiadlo, D. and S. Richardson, *The timed "Up & Go": a test of basic functional mobility for frail elderly persons*. *J Am Geriatr Soc*, 1991. **39**(2): p. 142-8.
31. Allali, G., et al., *Adapted timed up and go: a rapid clinical test to assess gait and cognition in multiple sclerosis*. *Eur Neurol*, 2012. **67**(2): p. 116-20.
32. Lallart, E., et al., *Gait and motor imagery of gait in early schizophrenia*. *Psychiatry research*, 2012. **198**(3): p. 366-370.
33. Beauchet, O., et al., *Imagined Timed Up & Go test: a new tool to assess higher-level gait and balance disorders in older adults?* *J Neurol Sci*, 2010. **294**(1-2): p. 102-6.
34. Laveneziana, P., et al., *ERS statement on respiratory muscle testing at rest and during exercise*. *Eur Respir J*, 2019. **53**(6).
35. Meek, P.M., et al., *Reliability and validity of the multidimensional dyspnea profile*. *Chest*, 2012. **141**(6): p. 1546-1553.
36. Banzett, R.B., et al., *Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research*. *Eur Respir J*, 2015. **45**(6): p. 1681-91.
37. Bahureksa, L., et al., *The Impact of Mild Cognitive Impairment on Gait and Balance: A Systematic Review and Meta-Analysis of Studies Using Instrumented Assessment*. *Gerontology*, 2017. **63**(1): p. 67-83.
38. McGough, E.L., et al., *Associations between physical performance and executive function in older adults with mild cognitive impairment: gait speed and the timed "up & go" test*. *Phys Ther*, 2011. **91**(8): p. 1198-207.
39. Cardebat, D., et al., *[Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level]*. *Acta Neurol Belg*, 1990. **90**(4): p. 207-17.
40. Reitan, R.M., *The relation of the trail making test to organic brain damage*. *J Consult Psychol*, 1955. **19**(5): p. 393-4.
41. Matsuda, O., et al., *Wechsler Adult Intelligence Scale-III profile in the early stages of Alzheimer's disease: performance in subtests sensitive to and resistant to normal decline with ageing*. *Psychogeriatrics*, 2015. **15**(1): p. 1-6.
42. Wechsler, D., *WAIS-IV : Wechsler adult intelligence scale*. 2008: Pearson Education, Inc.
43. Team, R.C., *R: A language and environment for statistical computing*. 2018, R Foundation for Statistical Computing, Vienna, Austria.

44. Bates, D., et al., *Fitting Linear Mixed-Effects Models Using lme4*. Journal of Statistical Software; Vol 1, Issue 1 (2015), 2015.
45. Lenth, R., *emmeans: Estimated Marginal Means, aka Least-Squares Means*. , in R package version 1.4.1. 2019.
46. (2017)., H.W., *tidyverse: Easily Install and Load the 'Tidyverse'*. . R package version 1.2.1.
47. Fritz, S. and M. Lusardi, *White paper: "walking speed: the sixth vital sign"*. J Geriatr Phys Ther, 2009. **32**(2): p. 46-9.
48. Studenski, S., et al., *Gait speed and survival in older adults*. Jama, 2011. **305**(1): p. 50-8.
49. Kon, S.S., et al., *Reliability and validity of 4-metre gait speed in COPD*. Eur Respir J, 2013. **42**(2): p. 333-40.
50. Kon, S.S., et al., *Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study*. Thorax, 2015. **70**(12): p. 1131-7.
51. Kon, S.S., et al., *The 4-metre gait speed in COPD: responsiveness and minimal clinically important difference*. Eur Respir J, 2014. **43**(5): p. 1298-305.
52. Karpman, C. and R. Benzo, *Gait speed as a measure of functional status in COPD patients*. Int J Chron Obstruct Pulmon Dis, 2014. **9**: p. 1315-20.
53. Blumen, H.M., et al., *Behavioral and neural correlates of imagined walking and walking-while-talking in the elderly*. Hum Brain Mapp, 2014. **35**(8): p. 4090-104.
54. Chang, S.S., et al., *Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults*. J Am Geriatr Soc, 2012. **60**(10): p. 1839-46.
55. Klein, M., et al., *Impact of chronic obstructive pulmonary disease (COPD) on attention functions*. Respir Med, 2010. **104**(1): p. 52-60.
56. Sachdev, P.S., et al., *Pulmonary function, cognitive impairment and brain atrophy in a middle-aged community sample*. Dementia and geriatric cognitive disorders, 2006. **21**(5-6): p. 300-308.
57. Hill, R.D., et al., *Cigarette smoking and cognitive performance in healthy Swedish adults*. Age and ageing, 2003. **32**(5): p. 548-550.
58. Haley, A.P., et al., *Carotid artery intima-media thickness and cognition in cardiovascular disease*. International journal of cardiology, 2007. **121**(2): p. 148-154.
59. Müllerova, H., et al., *Cardiovascular comorbidity in COPD: systematic literature review*. Chest, 2013. **144**(4): p. 1163-1178.
60. Stacey, D., L.G. Ciobanu, and B.T. Baune, *A systematic review on the association between inflammatory genes and cognitive decline in non-demented elderly individuals*. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017. **27**(6): p. 568-588.
61. Anblagan, D., et al., *Coupled changes in hippocampal structure and cognitive ability in later life*. Brain and behavior, 2018. **8**(2): p. e00838-e00838.
62. Johnson, M.J., et al., *Chronic breathlessness: re-thinking the symptom*. European Respiratory Journal, 2018. **51**(1): p. 1702326.
63. Morélot-Panzini, C., et al., *Breathlessness despite optimal pathophysiological treatment: on the relevance of being chronic*. European Respiratory Journal, 2017. **50**(3): p. 1701159.
64. Ramon, M.A., et al., *The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model*. Eur Respir J, 2018. **52**(3).
65. Adler, D., *Bridging the gap in knowledge between dyspnoea scientists and clinicians*. Eur Respir J, 2018. **52**(3).
66. Abdallah, S.J., et al., *Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial*. European Respiratory Journal, 2017. **50**(4): p. 1701235.
67. Herigstad, M., et al., *Treating breathlessness via the brain: changes in brain activity over a course of pulmonary rehabilitation*. The European respiratory journal, 2017. **50**(3): p. 1701029.

68. Stoeckel, M.C., et al., *Dyspnea catastrophizing and neural activations during the anticipation and perception of dyspnea*. *Psychophysiology*, 2018. **55**(4).
69. Hudson, A.L., et al., *Electroencephalographic detection of respiratory-related cortical activity in humans: from event-related approaches to continuous connectivity evaluation*. *J Neurophysiol*, 2016. **115**(4): p. 2214-23.
70. Banzett, R.B., et al., *Breathlessness in humans activates insular cortex*. *Neuroreport*, 2000. **11**(10): p. 2117-20.
71. Seino, T., et al., *Breathlessness-related Brain Activation: Electroencephalogram Dipole Modeling Analysis*. *The Showa University Journal of Medical Sciences*, 2015. **27**(1): p. 11-19.
72. Yanos, J., et al., *Ventilatory responses to inspiratory threshold loading in humans*. *Journal of applied physiology* (Bethesda, Md. : 1985), 1990. **68**(6): p. 2511-2520.
73. Stevens, J.P., et al., *Prevalence and Predictive Value of Dyspnea Ratings in Hospitalized Patients: Pilot Studies*. *PLoS One*, 2016. **11**(4): p. e0152601.



## TABLES

**Table 1: Baseline characteristics of participants**

\*Plus–minus values are means  $\pm$  standard deviation.

BMI, body mass index; FEV<sub>1</sub>: forced expiratory volume in 1 s, FVC; forced vital capacity; MIP; minimum MIP: mouth inspiratory pressure; SNIP: sniff nasal inspiratory pressure.

Characteristics*	Unloaded breathing first	Loaded breathing first	Total
	(n= 20)	(n=20)	(n=40)
Age - yr	26.35 $\pm$ 4.94	26.60 $\pm$ 5.14	26.48 $\pm$ 4.98
Male sex - n (%)	11 (55)	13 (65)	24 (60)
BMI - kg/m <sup>2</sup>	23.50 $\pm$ 4.00	22.98 $\pm$ 3.73	23.24 $\pm$ 3.82
FEV <sub>1</sub> /FVC - predicted %	101.15 $\pm$ 6.23	102.45 $\pm$ 8.20	101.80 $\pm$ 7.22
FEV <sub>1</sub> - predicted %	100.40 $\pm$ 11.25	101.30 $\pm$ 12.45	100.85 $\pm$ 11.72
MIP - cmH <sub>2</sub> O	111.65 $\pm$ 24.34	106.65 $\pm$ 25.86	109.15 $\pm$ 24.92
SNIP - cmH <sub>2</sub> O	104.00 $\pm$ 25.02	86.75 $\pm$ 20.82	95.38 $\pm$ 24.34
Level of inspiratory load provided by Powerbreath® device (from 1 to 9)	5.92 $\pm$ 2.28	4.33 $\pm$ 2.52	5.12 $\pm$ 2.51

**Table 2: Results summary**

The first row (a) depicts the mean difference between loaded and unloaded breathing, regardless of the arm, and its confidence interval estimated by the linear mixed model (the p-value corresponds to the test of this difference being equal to 0). The second row (b) depicts the mean difference between loaded and unloaded breathing and its confidence interval estimated by the linear mixed model for the experimental sequence “unloaded breathing first”. The third row (c) shows the mean difference between loaded and unloaded breathing and its confidence interval estimated by the linear mixed model for the experimental sequence “loaded breathing first”. The p-values presented in the 2nd and 3rd rows correspond to the result of the interaction test.

Tests		Beta	Beta 95% CI	p-value
<b>LOCOMOTION</b>				
TUG (seconds)	Overall <sup>a</sup>	-0.752	-1.012 to -0.492	<0.0001
	Unloaded 1st <sup>b</sup>	-0.403	-0.736 to -0.070	0.005
	Loaded 1st <sup>c</sup>	-1.101	-1.435 to -0.768	
iTUG (seconds)	Overall <sup>a</sup>	0.022	- 0.396 to 0.441	0.915
	Unloaded 1st <sup>b</sup>	0.341	-0.235 to 0.916	0.121
	Loaded 1st <sup>c</sup>	-0.296	-0.871 to 0.279	
Delta TUG (seconds)	Overall <sup>a</sup>	-0.081	-0.141 to -0.020	0.011
	Unloaded 1st <sup>b</sup>	-0.094	-0.180 to -0.008	0.666
	Loaded 1st <sup>c</sup>	-0.068	-0.153 to 0.018	
<b>EXECUTIVE FUNCTION</b>				
<b>Verbal Fluency (# word)</b>				
Categorical	Overall <sup>a</sup>	3.700	1.347 to 6.053	0.003
	Unloaded 1st <sup>b</sup>	0.500	-2.505 to 3.505	0.004
	Loaded 1st <sup>c</sup>	6.900	3.895 to 9.905	
Lexical	Overall <sup>a</sup>	0.725	-1.226 to 2.676	0.457
	Unloaded 1st <sup>b</sup>	-2.050	-4.515 to 0.415	0.003
	Loaded 1st <sup>c</sup>	3.500	1.035 to 5.965	
<b>Trail Making Test (seconds)</b>				
A	Overall <sup>a</sup>	-0.235	-1.813 to 1.344	0.765
	Unloaded 1st <sup>b</sup>	2.488	0.617 to 4.358	<0.0001
	Loaded 1st <sup>c</sup>	-2.957	-4.827 to -1.087	
B	Overall <sup>a</sup>	0.389	-4.769 to 5.547	0.880
	Unloaded 1st <sup>b</sup>	9.563	3.534 to 15.591	0.0001
	Loaded 1st <sup>c</sup>	-8.785	-14.813 to -2.756	
TMT B-TMT A	Overall <sup>a</sup>	0.624	- 4.648 to 5.896	0.812
	Unloaded 1st <sup>b</sup>	7.075	0.195 to 13.955	0.011
	Loaded 1st <sup>c</sup>	-5.828	-12.708 to 1.053	
<b>PROCESSING SPEED</b>				
CODE (# correct association)	Overall <sup>a</sup>	4.125	-0.265 to 8.515	0.065
	Unloaded 1st <sup>b</sup>	-6.800	-10.612 to -2.988	<0.0001
	Loaded 1st <sup>c</sup>	15.050	11.238 to 18.862	
<b>WORKING MEMORY</b>				
<b>Memory span (# correct sequence)</b>				
Direct	Overall <sup>a</sup>	0.325	- 0.174 to 0.824	0.196
	Unloaded 1st <sup>b</sup>	-0.200	-0.866 to 0.466	0.030
	Loaded 1st <sup>c</sup>	0.850	0.184 to 1.516	
Indirect	Overall <sup>a</sup>	0.050	-0.581 – 0.681	0.874
	Unloaded 1st <sup>b</sup>	-0.750	-1.568 to 0.068	0.008
	Loaded 1st <sup>c</sup>	0.850	0.032 to 1.668	

## Legends to the Figures

- **Figure 1: Study design\***

\*Randomized, open label, two-condition, two-period crossover design.

PFT= Pulmonary function tests, SNIP = sniff nasal inspiratory pressure, MIP = maximal inspiratory pressure, TUG= Timed Up and Go, iTUG= Imagined Timed Up and Go

- **Figure 2: TUG Test results**


Thick line within the box represents the median, the boundary of the box closest to zero indicates the 25<sup>th</sup> percentile and the farthest from zero indicates the 75<sup>th</sup> percentile, whiskers above and below the box indicate the 10<sup>th</sup> and 90<sup>th</sup> percentiles, points above the upper whisker indicates outliers outside the 90<sup>th</sup> percentiles.



***Panel A:***

Boxplots depicting subjects TUG test performance during the calm breathing phase compared to the experimentally induced dyspnea phase independently of experimental sequence.

***Panel B:***

Boxplots depicting subjects TUG test performance during the calm breathing phase compared to the experimentally induced dyspnea phase classified by experimental sequence.





## SUPPLEMENTARY MATERIAL

### Experimental dyspnea interferes with locomotion and cognition: a randomised trial

Lawi D<sup>1</sup>, Dupuis-Lozeron E<sup>2,7</sup>, Berra G<sup>1</sup>, Allali G<sup>3,4,7</sup>, Similowski T<sup>5,6</sup>, Adler D<sup>1,7</sup>

<sup>1</sup> Division of Pulmonary Diseases, Geneva University Hospitals, Geneva, Switzerland.

<sup>2</sup> Clinical Research Centre & Division of Clinical Epidemiology, Department of Health and Community Medicine, Geneva University Hospitals, Geneva, Switzerland.

<sup>3</sup> Department of Neurology, Geneva University Hospitals, Geneva, Switzerland.

<sup>4</sup> Department of Neurology, Division of Cognitive and Motor Aging, Albert Einstein College of Medicine, Bronx, NY, USA.

<sup>5</sup> AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Intensive Care Unit and Respiratory Division (Département "R3S"), Paris, France.

<sup>6</sup> Sorbonne University, UPMC Paris 06, INSERM, UMRS1158 Neurophysiologie respiratoire expérimentale et clinique, Paris, France.

<sup>7</sup> University of Geneva Faculty of Medicine, Geneva, Switzerland.

**Table S1: Results summary**

TESTS *	Calm breathing		Experimental dyspnea	
	Loaded breathing first	Unloaded breathing first	Loaded breathing first	Unloaded breathing first
LOCOMOTION				
TUG (seconds)	9.35 ± 1.50	8.95 ± 1.36	10.09 ± 1.53	8.99 ± 1.36
iTUG (seconds)	6.69 ± 2.23	7.03 ± 2.11	6.35 ± 1.55	6.05 ± 1.29
EXECUTIVE FUNCTION				
Verbal Fluency Test (# word)				
Categorical	34.9 ± 8.17	35.4 ± 8.34	29.80 ± 7.94	36.7 ± 8.04
Lexical	26.10 ± 6.58	24.05 ± 4.77	22.7 ± 7.77	26.20 ± 7.47
Trail Making Test (seconds)				
A	6.13 ± 3.10	18.61 ± 4.03	17.98 ± 4.56	15.02 ± 4.55
B	33.47 ± 10.81	43.04 ± 10.60	39.68 ± 12	30.90 ± 15.47
PROCESSING SPEED				
CODE (# correct association)	88.10 ± 14.81	81.3 ± 12.37	77 ± 15.42	92.05 ± 16.21
WORKING MEMORY				
Memory span (# correct sequence)				
Direct	10.5 ± 1.7	10.3 ± 1.3	9.3 ± 1.49	10.15 ± 1.63
Indirect	7.2 ± 2.24	6.45 ± 1.79	6.45 ± 1.88	7.3 ± 2.05

\*Plus-minus values are means ± standard deviation.

TUG : Test Up and Go, iTUG : imagined Test Up and Go, TMT : Trail Making Test, CODE: CODE test